Patents by Inventor Chia-Ing JAN

Chia-Ing JAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BAG6 SPECIFIC CHIMERIC ANTIGEN RECEPTOR, NUCLEIC ACID, BAG6 SPECIFIC CHIMERIC ANTIGEN RECEPTOR EXPRESSION PLASMID, BAG6 SPECIFIC CHIMERIC ANTIGEN RECEPTOR EXPRESSING CELL, USE THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER
    Publication number: 20240374726
    Abstract: A BAG6 specific chimeric antigen receptor, a nucleic acid, a BAG6 specific chimeric antigen receptor expression plasmid, a BAG6 specific chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the BAG6 specific chimeric antigen receptor expressing cell are provided. The BAG6 specific chimeric antigen receptor specifically binds to BCL2 associated athanogene 6 (BAG6). The nucleic acid encodes the BAG6 specific chimeric antigen receptor. The BAG6 specific chimeric antigen receptor expression plasmid expresses the BAG6 specific chimeric antigen receptor. The BAG6 specific chimeric antigen receptor expressing cell is obtained by transducing the BAG6 specific chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the BAG6 specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 3, 2024
    Publication date: November 14, 2024
    Applicant: China Medical University Hospital
    Inventors: Der-Yang Cho, Shao-Chih Chiu, Chia-Ing Jan, Chih-Ming Pan, Shi-Wei Huang
  • MULTISPECIFIC NANOBODIES CHIMERIC ANTIGEN RECEPTOR AND T-CELL ENGAGER, NUCLEIC ACID, EXPRESSING CELL THEREOF, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, AND METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELL
    Publication number: 20230038878
    Abstract: A multispecific nanobodies chimeric antigen receptor and T-cell engager includes an HLA-G nanobody chimeric antigen receptor and a bispecific T-cell engager. The HLA-G nanobody chimeric antigen receptor includes an HLA-G nanobodies unit, a transmembrane domain, and a CD3z signaling domain. The bispecific T-cell engager includes a PD-L1 nanobodies unit and a CD3e nanobody.
    Type: Application
    Filed: July 20, 2022
    Publication date: February 9, 2023
    Inventors: Der-Yang CHO, Shao-Chih CHIU, Shi-Wei HUANG, Chih-Ming PAN, Chia-Ing JAN, Mei-Chih CHEN, Yu-Chuan LIN, Chung-Chun WU
  • Nucleic acid, chimeric antigen receptor expression plasmid, chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer
    Patent number: 11554140
    Abstract: The present disclosure relates to a chimeric antigen receptor, a nucleic acid, a chimeric antigen receptor expression plasmid, a chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the chimeric antigen receptor expressing cell. The chimeric antigen receptor is specific to human leukocyte antigen G. The nucleic acid encodes the chimeric antigen receptor. The chimeric antigen receptor expression plasmid expresses the chimeric antigen receptor. The chimeric antigen receptor expressing cell is obtained by transducing the chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: January 17, 2023
    Assignee: China Medical University Hospital
    Inventors: Der-Yang Cho, Shao-Chih Chiu, Chia-Ing Jan, Chih-Ming Pan, Shi-Wei Huang
  • HLA-G specific chimeric antigen receptor, nucleic acid, HLA-G specific chimeric antigen receptor expression plasmid, HLA-G specific chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer
    Patent number: 11479611
    Abstract: The present disclosure relates to a HLA-G specific chimeric antigen receptor, a nucleic acid, a HLA-G specific chimeric antigen receptor expression plasmid, a HLA-G specific chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the HLA-G specific chimeric antigen receptor expressing cell. The chimeric antigen receptor specifically binds to human leukocyte antigen G. The nucleic acid encodes the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expression plasmid expresses the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expressing cell is obtained by transducing the HLA-G specific chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the HLA-G specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: October 25, 2022
    Assignee: China Medical University Hospital
    Inventors: Der-Yang Cho, Shao-Chih Chiu, Chia-Ing Jan, Chih-Ming Pan, Shi-Wei Huang
  • HLA-G Specific Chimeric Antigen Receptor, Nucleic Acid, HLA-G Specific Chimeric Antigen Receptor Expression Plasmid, HLA-G Specific Chimeric Antigen Receptor Expressing Cell, Use Thereof, And Pharmaceutical Composition For Treating Cancer
    Publication number: 20210122825
    Abstract: The present disclosure relates to a HLA-G specific chimeric antigen receptor, a nucleic acid, a HLA-G specific chimeric antigen receptor expression plasmid, a HLA-G specific chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the HLA-G specific chimeric antigen receptor expressing cell. The chimeric antigen receptor specifically binds to human leukocyte antigen G. The nucleic acid encodes the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expression plasmid expresses the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expressing cell is obtained by transducing the HLA-G specific chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the HLA-G specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 2, 2020
    Publication date: April 29, 2021
    Applicant: China Medical University Hospital
    Inventors: Der-Yang Cho, Shao-Chih Chiu, Chia-Ing Jan, Chih-Ming Pan, Shi-Wei Huang
  • Chimeric Antigen Receptor, Nucleic Acid, Chimeric Antigen Receptor Expression Plasmid, Chimeric Antigen Receptor Expressing Cell, Use Thereof, And Pharmaceutical Composition For Treating Cancer
    Publication number: 20200216543
    Abstract: The present disclosure relates to a chimeric antigen receptor, a nucleic acid, a chimeric antigen receptor expression plasmid, a chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the chimeric antigen receptor expressing cell. The chimeric antigen receptor is specific to human leukocyte antigen G. The nucleic acid encodes the chimeric antigen receptor. The chimeric antigen receptor expression plasmid expresses the chimeric antigen receptor. The chimeric antigen receptor expressing cell is obtained by transducing the chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 22, 2019
    Publication date: July 9, 2020
    Inventors: Der-Yang Cho, Shao-Chih Chiu, Chia-Ing Jan, Chih-Ming Pan, Shi-Wei Huang
  • Method For Treating Cancer
    Publication number: 20200085868
    Abstract: The present disclosure relates to a method for treating cancer including steps as follows. A chemotherapy drug is administered to a subject in need for a treatment of cancer. Then a composition containing a plurality of chimeric antigen receptor expressing cells is administered to the subject, wherein the chimeric antigen receptor expressing cells expresses a chimeric antigen receptor specific to human leukocyte antigen G (HLA-G).
    Type: Application
    Filed: April 22, 2019
    Publication date: March 19, 2020
    Inventors: Der-Yang Cho, Shao-Chih Chiu, Chia-Ing Jan, Chih-Ming Pan, Shi-Wei Huang
  • Method of evaluating glioblastoma multiforme patient applicable to immunotherapy treatment based on dendritic cell tumor vaccines and method of prognosticating survival rate in glioblastoma mulztiforme patient after treatment
    Patent number: 10036751
    Abstract: A method of evaluating if a glioblastoma multiforme (GBM) patient is applicable to be treated with an immunotherapy based on dendritic cell tumor vaccines includes a sample obtaining step to obtain a sample from the GBM patient, a detecting step to detect an expression level of a biomarker, and a comparing step to compare the expression level of the biomarker to a threshold, wherein the GBM patient is applicable to treat with the immunotherapy based on dendritic cell tumor vaccines when the expression level of the biomarker is lower than the threshold. A method of prognosticating a survival rate in the GBM patient after a treatment includes a sample obtaining step, a detecting step, and a comparing step, wherein the GBM patient is determined to have a good prognosis after the treatment when the expression level of the sample from the GBM is lower than the threshold.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: July 31, 2018
    Assignee: China Medical University Hospital
    Inventors: Der-Yang Cho, Shao-Chih Chiu, Chia-Ing Jan
  • METHOD OF EVALUATING GLIOBLASTOMA MULTIFORME PATIENT APPLICABLE TO IMMUNOTHERAPY TREATMENT BASED ON DENDRITIC CELL TUMOR VACCINES AND METHOD OF PROGNOSTICATING SURVIVAL RATE IN GLIOBLASTOMA MULZTIFORME PATIENT AFTER TREATMENT
    Publication number: 20170045516
    Abstract: A method of evaluating if a glioblastoma multiforme (GBM) patient is applicable to be treated with an immunotherapy based on dendritic cell tumor vaccines includes a sample obtaining step to obtain a sample from the GBM patient, a detecting step to detect an expression level of a biomarker, and a comparing step to compare the expression level of the biomarker to a threshold, wherein the GBM patient is applicable to treat with the immunotherapy based on dendritic cell tumor vaccines when the expression level of the biomarker is lower than the threshold. A method of prognosticating a survival rate in the GBM patient after a treatment includes a sample obtaining step, a detecting step, and a comparing step, wherein the GBM patient is determined to have a good prognosis after the treatment when the expression level of the sample from the GBM is lower than the threshold.
    Type: Application
    Filed: May 16, 2016
    Publication date: February 16, 2017
    Inventors: Der-Yang CHO, Shao-Chih CHIU, Chia-Ing JAN